Rays of Belief Limited (NSE: MOMSBELIEF, BSE: 544906) is a Gurugram, Haryana-based company in the Pharmaceutical CDMO and CRO Services industry. With a market capitalisation of ₹536 Cr, it ranks #1,968 by market cap among the 6,197 Indian listed companies on FinBizNet, and #11 of 11 in Pharmaceutical CDMO and CRO Services. At ₹273.61 (as of 19 Nov 2026), the share price is 13.1% below its 52-week high of ₹314.95 and 36.1% above its 52-week low of ₹201.10.
| Current Price | ₹273.61 |
|---|---|
| Market Cap | ₹536 Cr |
| NSE Symbol | MOMSBELIEF |
| BSE Code | 544906 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services |
| P/E Ratio | 90.6 |
| Return on Assets | 12.31% |
| 52-Week Range | ₹201.10 – ₹314.95 |
| Beta (1Y) | -3.43 |
| Headquarters | Gurugram, Haryana |
| Website | www.momsbelief.com |
| Revenue | ₹27 Cr |
|---|---|
| Net Profit | ₹3 Cr |
| Net Margin | 12.7% |
| EPS (Basic) | ₹2.00 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Promoters held 68.77% of Rays of Belief Limited's shares as of Sept 2026. Delivery averaged 29.0% of traded volume across 18 NSE sessions (26 Oct 2026 – 19 Nov 2026).
Rays of Belief Limited operates as a holistic care provider for children with autism, ADHD, Down syndrome, and other developmental delays and disorders in India. The company provides subscription-based, guided therapy programs designed to empower parents of children with special needs. The company operates through its brand, Mom’s Belief, a child development and therapy organization that creates personalized therapeutic programs for children with autism and other developmental delays. The company's services include occupational therapy to enhance motor skills and daily functioning; speech therapy to improve communication and language abilities; special education and individualized learning support for children with diverse needs; Applied Behaviour Analysis (ABA), a behaviour-based intervention for skill development; language and communication therapy to strengthen verbal and social communication; and adult counselling to support parents and caregivers. Rays of Belief Limited was incorp
1. Healthcare Facilities & Services-This segment provides intervention plans for children with neurodevelopmental disorders. 2. NA-NA 3. NA-NA 4. NA-NA
1. Healthcare Facilities & Services-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Divis Laboratories Limited | ₹3,01,758 Cr | 118.4 | 16.19% | ₹3,676 Cr | +69.5% |
| Anthem Biosciences Limited | ₹53,926 Cr | 90.1 | 19.45% | ₹594 Cr | +34.3% |
| Sai Life Sciences Limited | ₹40,755 Cr | 116.1 | 15.13% | ₹659 Cr | +105.6% |
| Onesource Specialty Pharma Limited | ₹18,138 Cr | n/m | -1.26% | ₹516 Cr | -8.2% |
| Cohance Lifesciences Ltd | ₹17,756 Cr | 100.6 | 5.11% | ₹477 Cr | -26.9% |
| Syngene International Ltd. | ₹17,630 Cr | 56.9 | 6.62% | ₹833 Cr | -34.1% |
| Jubilant Pharmova Ltd | ₹15,556 Cr | 39.1 | 5.96% | ₹2,370 Cr | -16.9% |
| Concord Biotech Ltd | ₹12,495 Cr | 24.2 | 13.54% | ₹309 Cr | -23.7% |
| Rays of Belief Limited | ₹536 Cr | 90.6 | — | ₹27 Cr | — |
Listed by market capitalisation. Ratios are shown for context only.
Rays of Belief Limited is trading at ₹273.61, with a market capitalisation of ₹536 Cr.
Rays of Belief Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services).
Rays of Belief Limited has a P/E of 90.6.
Rays of Belief Limited is listed on the NSE under the symbol MOMSBELIEF and on the BSE under the scrip code 544906.
In Q2 FY27, Rays of Belief Limited reported revenue of ₹27 Cr and net profit of ₹3 Cr, with basic EPS of ₹2 (consolidated, parsed from the company's exchange filing).
Promoters held 68.77% of Rays of Belief Limited's shares as of Sept 2026.
Data as of 19 Nov 2026. Descriptive market data only — not investment advice.